Salim Syed
Stock Analyst at Mizuho
(2.41)
# 2,523
Out of 5,135 analysts
77
Total ratings
45.16%
Success rate
1.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Upgrades: Outperform | $90 → $121 | $102.99 | +17.49% | 1 | Dec 8, 2025 | |
| ASMB Assembly Biosciences | Maintains: Outperform | $29 → $40 | $28.80 | +38.89% | 2 | Nov 20, 2025 | |
| NKTX Nkarta | Maintains: Outperform | $16 → $14 | $2.23 | +527.80% | 8 | Jun 10, 2025 | |
| CYTK Cytokinetics | Maintains: Outperform | $103 → $84 | $66.98 | +25.41% | 7 | May 29, 2025 | |
| BIIB Biogen | Maintains: Outperform | $207 → $169 | $194.13 | -12.94% | 16 | May 7, 2025 | |
| AMGN Amgen | Maintains: Neutral | $235 → $280 | $379.73 | -26.26% | 8 | May 7, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $100 → $117 | $152.74 | -23.40% | 7 | May 5, 2025 | |
| WVE Wave Life Sciences | Maintains: Outperform | $19 → $22 | $13.09 | +68.07% | 5 | Nov 21, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $113 → $163 | $56.17 | +190.19% | 3 | Sep 10, 2024 | |
| ATRA Atara Biotherapeutics | Upgrades: Outperform | $25 → $18 | $4.44 | +305.41% | 4 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $26.37 | +28.93% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $99 | $53.52 | +84.98% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $53 | $73.93 | -28.31% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $1.63 | +1,188.34% | 5 | Nov 16, 2022 |
Incyte
Dec 8, 2025
Upgrades: Outperform
Price Target: $90 → $121
Current: $102.99
Upside: +17.49%
Assembly Biosciences
Nov 20, 2025
Maintains: Outperform
Price Target: $29 → $40
Current: $28.80
Upside: +38.89%
Nkarta
Jun 10, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $2.23
Upside: +527.80%
Cytokinetics
May 29, 2025
Maintains: Outperform
Price Target: $103 → $84
Current: $66.98
Upside: +25.41%
Biogen
May 7, 2025
Maintains: Outperform
Price Target: $207 → $169
Current: $194.13
Upside: -12.94%
Amgen
May 7, 2025
Maintains: Neutral
Price Target: $235 → $280
Current: $379.73
Upside: -26.26%
Gilead Sciences
May 5, 2025
Maintains: Outperform
Price Target: $100 → $117
Current: $152.74
Upside: -23.40%
Wave Life Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $19 → $22
Current: $13.09
Upside: +68.07%
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $56.17
Upside: +190.19%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $4.44
Upside: +305.41%
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $26.37
Upside: +28.93%
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $53.52
Upside: +84.98%
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $73.93
Upside: -28.31%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $1.63
Upside: +1,188.34%